Hair Loss Now: Minoxidil, Finasteride & What’s Coming Next

Hair loss has become a crowded marketplace of serums, supplements, and devices that promise regrowth. Underneath the noise, two drugs still do most of the heavy lifting: minoxidil and finasteride. Around them, a new wave of pharmacologic, device-based, and regenerative therapies is emerging, some with solid data, many with early but intriguing signals.[2][3][4][11][15]

This piece looks at what is established, what is genuinely promising, and how a realistic, evidence-forward plan might come together for androgenetic alopecia (pattern hair loss) in men and women.

What the science says

The core problem: miniaturizing follicles

Androgenetic alopecia (AGA) is the most common form of hair loss worldwide, affecting up to about half of men and a large proportion of women by midlife.[3][5] It is driven by a mix of genetics, hormones, inflammation, and local signaling in the hair follicle.[3][5][15]

At the follicle level, several recurring themes show up:

• Dihydrotestosterone (DHT) and androgens drive progressive “miniaturization” of susceptible follicles in AGA, especially in men.[2][3][5]
• The anagen (growth) phase shortens, while telogen (resting) and shedding proportions increase.[1][4][5]
• Microinflammation, oxidative stress, and altered Wnt/β‑catenin signaling contribute to follicle deterioration and impaired regeneration.[3][4][5][15]

Effective treatments tend to do one or more of three things:

1. Reduce androgen signaling at the follicle (finasteride, dutasteride, topical antiandrogens).[2][3][4][6][11]
2. Prolong anagen and increase blood flow or follicular metabolism (minoxidil, low-level laser therapy, microneedling).[3][4][5][10][11]
3. Actively regenerate or rescue follicular structures (PRP, stem cell–based strategies, exosomes).[4][5][7]

Why minoxidil and finasteride are still first-line

Despite an expanding menu of interventions, multiple recent reviews come to the same conclusion: topical minoxidil and oral finasteride remain the most studied, guideline-backed options for male AGA, with minoxidil also a mainstay in women.[2][3][11][12][15]

• A 2025 review of male AGA recommends starting with topical minoxidil and oral finasteride based on the depth of evidence and regulatory approval status in many countries.[2]
• Systematic and narrative reviews consistently find both drugs superior to placebo for increasing hair count and slowing progression, though neither restores juvenile density or works for everyone.[3][11][15]

Emerging therapies are, for now, mostly add-ons or alternatives for those who cannot tolerate or do not respond adequately to these anchors.[2][3][4][5][6][11]

How it works

Minoxidil: pushing follicles into growth

Minoxidil was originally an oral antihypertensive; hair growth was a side effect that became the main event when applied topically.

Mechanistically, minoxidil:

• Acts as a potassium channel opener, enhancing vasodilation and scalp blood flow.[11][15]
• Prolongs the anagen phase and can enlarge miniaturized follicles.[3][5][11]
• Likely upregulates growth factors and prostaglandin pathways that favor follicle activity.[11][15]

Historically, minoxidil has been used as topical solutions or foams (2–5%), applied once or twice daily.[2][3][11] More recently, low-dose oral minoxidil (LDOM) has gained attention as an off-label systemic option.[6][12][14]

Finasteride: turning down DHT

Finasteride is a type II 5‑α‑reductase inhibitor, blocking the conversion of testosterone to DHT, the androgen most strongly linked with follicle miniaturization in male AGA.[2][3][11][15]

• Lowering scalp DHT helps stabilize or reverse miniaturization and increases hair count in a subset of men.[2][3][11]
• Standard oral dosing for AGA is typically 1 mg daily in men; response often plateaus after 1–2 years, with continued use needed to maintain gains.[2][3][11]

Topical finasteride formulations aim to reduce scalp DHT while limiting systemic exposure, a strategy supported by pharmacokinetic and early clinical data but not yet fully standardized.[6][12][14]

The new kids: antiandrogen creams, JAK inhibitors, and beyond

Emerging small molecules and biologics tend to refine, rather than reinvent, existing mechanisms:

• Topical antiandrogens such as pyrilutamide (KX‑826) and clascoterone act at the androgen receptor in the follicle, attempting to blunt androgen effects without meaningful systemic hormone suppression.[3][4][6][13]
• JAK inhibitors—already used in alopecia areata—are being explored for AGA and other forms of hair loss where immune signaling intersects with follicular cycling, but data in AGA remain early.[3][4][7][13]
• Wnt activators and SFRP1 antagonists target developmental pathways that govern follicle stem cell activation and cycling, largely still at preclinical or very early clinical stages.[1][4][11][15]

Regenerative approaches and devices

Mechanobiology and regenerative medicine add a structural and microenvironmental layer:

• Platelet-rich plasma (PRP) delivers a concentrated cocktail of growth factors that may stimulate dermal papilla cells, angiogenesis, and anagen entry.[4][5][11][14]
• Mesenchymal stem cells, exosomes, and conditioned media seek to provide regenerative signals that promote follicle repair and neogenesis.[4][5][7][13][15]
• Low-level laser/light therapy (LLLT) and fractional lasers use controlled photobiomodulation and microinjury to alter follicular signaling and, in some cases, increase penetration of topical drugs.[5][10][11]
• Microneedling and other mechanical stimulation techniques may activate wound-healing pathways that favor hair growth and enhance topical absorption.[1][3][5][11]

What the evidence supports

1. Established therapies: strong clinical backing

Topical minoxidil

• Multiple randomized trials show minoxidil improves hair count and global appearance vs placebo in both men and women with AGA, with effects emerging after 3–6 months.[2][3][11]
• Benefits are dose- and adherence-dependent; continued use is required to maintain regrowth.[2][3][11]

Oral finasteride (men)

• Long-term studies in male AGA demonstrate that finasteride can slow progression and increase hair count compared with placebo, particularly when started early.[2][3][11]
• The drug is generally effective but not universal: some men are non‑responders or experience only stabilization.[2][3][11]

These two agents still represent the most evidence-supported pharmacologic foundation for AGA, especially in men.[2][3][11][15]

2. Off-label, but increasingly studied

Low-dose oral minoxidil (LDOM)

• LDOM has rapidly grown in research volume as an off-label alternative or adjunct to topical formulations.[6][12][14]
• Observational studies and small trials suggest dose-dependent improvements in hair density across various alopecias, with side effects including hypertrichosis, edema, and rare cardiovascular issues at low doses.[6][14]
• A recent bibliometric analysis highlights LDOM as a major emerging theme in AGA research.[12]

Topical finasteride

• Data show that properly formulated topical finasteride can significantly suppress scalp DHT while minimizing systemic DHT reduction compared with oral dosing.[6][12][14]
• Early clinical trials report improvements in hair density similar to oral finasteride in some cohorts, but large head-to-head, long-term studies are still limited.[6][12]

3. Emerging pharmacologics

Topical AR antagonists (pyrilutamide, clascoterone)

• Early-phase trials of pyrilutamide (KX‑826) show promising increases in target area hair count in men with AGA, with mainly local side effects reported so far.[3][4][6][13]
• Clascoterone, already approved as an acne therapy, is being studied off-label and in early trials for hair loss with the rationale of local androgen receptor blockade.[3][6][13]

JAK inhibitors and novel small molecules

• JAK inhibitors are well established for alopecia areata; for AGA, their role remains speculative and early-stage.[3][4][7][13]
• Broader “hair loss drug development” pipelines include kinase inhibitors, prostaglandin analogues, and Wnt pathway modulators, most still in preclinical or Phase 1/2 studies.[13][15]

4. Regenerative and device-based therapies

Platelet-rich plasma (PRP)

• Reviews describe PRP as one of the best-studied regenerative options for AGA, with many—though not all—trials reporting improved hair density and shaft thickness, especially when combined with minoxidil or finasteride.[4][5][11][14]
• Heterogeneity in PRP preparation and injection protocols makes cross-study comparison difficult.[4][5][14]

Stem cells, exosomes, and conditioned media

• Mesenchymal stem cells and their exosomes have demonstrated the ability to activate dermal papilla cells, stimulate Wnt/β‑catenin signaling, and enhance angiogenesis in preclinical and early clinical work.[4][5][7][13][15]
• Early human studies show increases in hair density and thickness, but sample sizes are small and long-term safety and durability are not yet clear.[4][7][13]

LLLT and fractional lasers

• Low-level laser/light devices have accumulated enough evidence to be considered a reasonably effective and safe adjunct for some patients with AGA.[5][10][11]
• Fractional lasers show positive signals in small series, possibly by inducing microinjury and enhancing topical penetration, but robust randomized trials are still needed.[10][11]

Mechanobiological approaches & microneedling

• Microneedling, microcurrent, and other mechanical stimulation techniques are being actively explored as non-drug ways to promote anagen and enhance topical drug delivery.[1][3][5][11]
• Early data, especially when combined with minoxidil, are encouraging but methodologically heterogeneous.[3][11]

Practical takeaways

For readers navigating real-world decisions, the hierarchy looks something like this for androgenetic alopecia:

1. Start with the workhorses (assuming no contraindications and after medical evaluation):

   • Men: topical minoxidil ± oral finasteride as foundational therapy.[2][3][11]
   • Women: topical minoxidil as first-line; systemic antiandrogens or finasteride/dutasteride are specialist decisions, particularly in premenopausal women.[3][5][11]

2. Consider off-label but better-studied add-ons with a dermatologist familiar with hair disorders:

   • Low-dose oral minoxidil for those who cannot tolerate or adhere to topical regimens.[6][12][14]
   • Topical finasteride (or other topical 5‑α‑reductase inhibitors) to reduce systemic exposure while targeting scalp DHT.[6][12][14]
   • LLLT devices as an adherence-friendly adjunct for some patients.[5][10][11]

3. Explore emerging options where expectations are calibrated:

   • PRP in clinics with expertise and transparent protocols, ideally as a complement to minoxidil/finasteride rather than a standalone fix.[4][5][11][14]
   • Clinical trials involving topical AR antagonists, exosomes, or stem cell–based approaches for those willing to accept uncertainty in exchange for early access.[3][4][7][13]

4. Anchor everything in long-term thinking:

   • Most effective therapies require ongoing use; stopping them typically leads to gradual loss of gains.[2][3][11]
   • Combination, multimodal strategies increasingly outperform monotherapy in the literature, especially when started early.[3][4][5]

Caveats and unknowns

Side effects and safety signals

• Finasteride: Sexual side effects, mood changes, and concerns about “post-finasteride syndrome” are widely discussed; while causal links and prevalence remain debated, guidelines recommend informed consent and monitoring.[2][3][11][15]
• Low-dose oral minoxidil: Even low doses can cause hypertrichosis, edema, and cardiovascular effects in susceptible individuals, warranting careful selection and follow-up.[6][14]
• Regenerative therapies: Long-term safety of repeated PRP, stem cell products, and exosomes is not fully mapped, particularly regarding fibrosis, aberrant growth, or immune reactions.[4][5][7][13]

Heterogeneous protocols and hype

Many of the most intriguing therapies—PRP, microneedling, exosomes, stem cells—suffer from a similar problem: no standardized protocols and highly variable study quality.[3][4][5][7][10][14]

• Different preparation systems, dosing intervals, and outcome measures make it difficult to compare results or give precise, evidence-based “recipes.”[4][5][14]
• Commercial offerings often move faster than the data, with marketing sometimes outpacing peer-reviewed evidence.[5][7][13]

Regeneration vs. rescue

Preclinical work in mechanobiology and follicle regeneration hints at a future in which we might reliably regenerate robust follicles from stem cells or bioengineered structures.[1][4][5][7][15]

• For now, most interventions are better at rescuing miniaturizing follicles than reviving long-dead ones.[3][5][11]
• Advanced or long-standing baldness remains challenging; hair transplantation, often in combination with medical therapy, is still a mainstay where donor supply is adequate.[5][14]

Disease heterogeneity

Finally, AGA is only one of several causes of hair loss. Telogen effluvium, alopecia areata, scarring alopecias, and nutritional or endocrine causes all require distinct workups and treatments.[3][5][7][11]

That makes early, accurate diagnosis by a clinician experienced in hair disorders the true first step—before any bottle, pill, laser cap, or vial of plasma enters the picture.